Literature DB >> 19180107

Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'.

Nicolas André, Eddy Pasquier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19180107     DOI： 10.1038/ncponc1317

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN： 1743-4254


× No keyword cloud information.
  9 in total

1.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.

Authors:  M Kavallaris; D Y Kuo; C A Burkhart; D L Regl; M D Norris; M Haber; S B Horwitz
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence.

Authors:  Chia-Ping Huang Yang; Pascal Verdier-Pinard; Fang Wang; Eva Lippaine-Horvath; Lifeng He; Dansu Li; Gerhard Höfle; Iwao Ojima; George A Orr; Susan Band Horwitz
Journal:  Mol Cancer Ther       Date:  2005-06       Impact factor: 6.261

3.  Intermittent androgen blockade should be regarded as standard therapy in prostate cancer.

Authors:  Bostjan Seruga; Ian F Tannock
Journal:  Nat Clin Pract Oncol       Date:  2008-07-15

4.  Novel nucleolar and nuclear morphology in a vincristine-dependent human leukemia cell line (L100).

Authors:  L M Slater; P Sweet; T C Hsu; P K Chan
Journal:  Exp Cell Res       Date:  1992-01       Impact factor: 3.905

5.  Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice.

Authors:  Chih-pin Chuu; Richard A Hiipakka; Junichi Fukuchi; John M Kokontis; Shutsung Liao
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 12.701

6.  The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death?

Authors:  V Craig Jordan
Journal:  J Clin Oncol       Date:  2008-06-02       Impact factor: 44.544

7.  Stopping treatment can reverse acquired resistance to letrozole.

Authors:  Gauri J Sabnis; Luciana F Macedo; Olga Goloubeva; Adam Schayowitz; Angela M H Brodie
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

8.  Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division.

Authors:  F R Cabral
Journal:  J Cell Biol       Date:  1983-07       Impact factor: 10.539

9.  Taxol-dependent mutants of Chinese hamster ovary cells with alterations in alpha- and beta-tubulin.

Authors:  M J Schibler; F Cabral
Journal:  J Cell Biol       Date:  1986-04       Impact factor: 10.539
  9 in total
  6 in total

Review 1.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

2.  Stochastic dynamics of leukemic cells under an intermittent targeted therapy.

Authors:  Nicola Pizzolato; Dominique Persano Adorno; Davide Valenti; Bernardo Spagnolo
Journal:  Theory Biosci       Date:  2011-04-09       Impact factor: 1.919

3.  Pilot study of a pediatric metronomic 4-drug regimen.

Authors:  Nicolas André; Sylvie Abed; Daniel Orbach; Corinne Armari Alla; Laetitia Padovani; Eddy Pasquier; Jean Claude Gentet; Arnauld Verschuur
Journal:  Oncotarget       Date:  2011-12

Review 4.  Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key.

Authors:  Connie Rabanal; Rossana Ruiz; Silvia Neciosup; Henry Gomez
Journal:  World J Clin Oncol       Date:  2017-12-10

Review 5.  Metronomic chemotherapy.

Authors:  Rituparna Maiti
Journal:  J Pharmacol Pharmacother       Date:  2014-07

6.  Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach.

Authors:  Farshad Moradi Kashkooli; M Soltani
Journal:  Sci Rep       Date:  2021-11-02       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.